A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Yellin, Michael; Paliienko, I.A.; Bălănescu, Andra; Ter-Vartanian, S.Kh.; Tseluyko, Vira; Xu, Li‐An; Tao, Xiaolu; M. Cardarelli, Pina; Leblanc, Heidi; Nichol, Geoff; Ancuța, Codrina; Chirieac, Rodica; Luo, Allison

doi:10.1002/art.34330

Public

A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Published in Arthritis & Rheumatism • Dec 6, 2011

Authors:

Michael Yellin

I.A. Paliienko

Andra Bălănescu

Abstract

OBJECTIVE: CXCL10 (also known as interferon-γ-inducible 10-kd protein [IP-10]) is a chemokine that potentially plays a role in the immunopathogenesis of rheumatoid arthritis (RA). We undertook this phase II study to evaluate the efficacy and safety of MDX-1100, a fully human, anti-CXCL10 (anti-IP-10...

Subject

Medicine

Rheumatoid arthritis

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!